Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...

In this video, Sham Mailankody, MBBS discusses methods to stay aware of the threat of multiple myeloma relapse.

Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer of the blood—also known as hematologic cancer. It affects cells called plasma cells, which are types of white blood ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population. The 66th ...

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector. The FDA granted approval to AstraZeneca AZN and partner Daiichi’s novel TROP2 ...

Multiple myeloma causes changes in the blood cells that may lead to physical signs and symptoms. When you see your healthcare provider, they will probably ask about your symptoms and when they began.

He previously worked at Android Police and Tech Advisor. Google’s AI assistant Gemini is now able to carry out tasks across multiple apps in a single interaction, in an update announced today ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The Bells of Hope community provides support and inspiration, fostering unity ...

Anitocabtagene autoleucel is under clinical development by Arcellx and currently in Phase III for Relapsed Multiple Myeloma. According to GlobalData, Phase III drugs for Relapsed Multiple Myeloma have ...

Carvykti and Abecma could soon have new competition from Gilead Sciences and partner Arcellx, which in November 2024 touted strong response rates and promising survival outcomes from a registrational ...